| Han Ma |
Han Ma has worked at BeOne Medicines Ltd. since 2021 as Chief Safety Officer & SVP-al Patient Safety. |
| Lai Wang |
Lai Wang currently works at BeOne Medicines Ltd., as Global Head-Research & Development from 2021. Mr. Wang also formerly worked at Joyant Pharmaceuticals, Inc., as Director-Research. Mr. Wang received his undergraduate degree in 1996 from Fudan University and doctorate degree in 2001 from The University of Texas Health Science Center at Houston. |
| Mark Lanasa |
Mark Lanasa currently works at BeOne Medicines Ltd., as Chief Medical Officer-Solid Tumors & SVP from 2022. Mr. Lanasa also formerly worked at AstraZeneca PLC, as Vice President & Head-Enhertu Global Clinical from 2019 to 2022. Mr. Lanasa received his undergraduate degree from The Pennsylvania State University and graduate degree and doctorate degree from the University of Pittsburgh School of Medicine. |
| Julie Lepin |
Julie Lepin currently works at BeiGene Ltd., as Chief Regulatory Affairs Officer & Senior VP from 2024. Ms. Lepin received her graduate degree from the University of Cardiff and undergraduate degree from King's College London. |
| Aaron Rosenberg |
Aaron Rosenberg currently works at ArQule, Inc., as Treasurer, Director & Senior Vice President, Acceleron Pharma, Inc., as Treasurer, Director & Senior Vice President from 2021, Harrisvaccines LLC, as Treasurer & Director, Imago BioSciences, Inc., as Treasurer, Director & Senior Vice President from 2023, Prometheus Biosciences, Inc., as Director from 2023, and BeOne Medicines Ltd., as Chief Financial Officer from 2024. Mr. Rosenberg also formerly worked at Merck & Co., Inc., as Treasurer & Senior Vice President from 2021 to 2024. Mr. Rosenberg received his Masters Business Admin degree from The Leonard N Stern School of Business and undergraduate degree from Warrington College of Business Administration. |
| Yang Ji |
Yang Ji currently works at BeiGene Ltd., as Chief Compliance Officer from 2017. Mr. Ji received his Masters Business Admin degree from Peking University. |
| Eva Yin |
Eva Yin currently works at BeiGene Ltd., as Chief Commercial Officer. Ms. Yin also formerly worked at AstraZeneca LP, as VP-Commercial & Channel from 2006 to 2021. Ms. Yin received her Masters Business Admin degree from China Europe International Business School. |
| Titus Benjamin Ball |
Titus Benjamin Ball currently works at Arbo (Holdings) Ltd., as Director from 2017, Adshead Ratcliffe & Co. Ltd., as Director from 2017, Raydex, as Director, Carlisle Interconnect Technologies Ltd., as Director, Carlisle Holdings GmbH, as Co-Managing Director from 2020, Carlisle Holding Ltd., as Director from 2017, Carlisle Construction Materials Ltd., as Director from 2017, Carlisle International Holdings Ltd., as Director from 2017, Carlisle Global II Ltd., as Director from 2019, Carlisle Fluid Technologies, Inc., as Vice President-Finance from 2021, and BeiGene Ltd., as Chief Accounting Officer & Vice President from 2024. Mr. Ball also formerly worked at KPMG US LLP, as Managing Director from 2022 to 2023 and Carlisle Cos., Inc., as Chief Accounting Officer & Vice President from 2016 to 2021. Mr. Ball received his undergraduate degree from King University. |
| Xiao Dong Wang |
Xiao Dong Wang is the founder of Joyant Pharmaceuticals, Inc. (2004), National Institute of Biological Sciences (2003), Sironax Ltd. (2017), and BeOne Medicines Ltd. (2010). Current jobs include Non-Executive Director at Clover Biopharmaceuticals Ltd. (2021), Foreign Associate at Chinese Academy of Sciences (2013), Member at National Academy of Sciences (2004), and Professor at Tsinghua University (2020). Former jobs include Professor at Howard Hughes Medical Institute, Inc. and Professor at The University of Texas Southwestern Medical Center (2001-2010). Education includes an undergraduate degree from Beijing Normal University (1984) and a doctorate from The University of Texas Southwestern Medical Center. |
| John V. Oyler |
John V. Oyler was the founder of Telephia, Inc. (1997), serving as President; BioDuro LLC (2005), serving as Chief Executive Officer; and BeOne Medicines Ltd. (2010), serving as Chairman & Chief Executive Officer. Mr. Oyler is currently the CEO, CFO, Secretary & Director at BeiGene USA, Inc. Former positions include Co-Chief Executive Officer at Genta, Inc. (1997-1998), Chief Executive Officer at Galenea Corp. (2002-2004), Director at Biotechnology Innovation Organization (2019-2024), Principal at McKinsey & Co., Inc., Vice President-Operations at Walden Laboratories, Inc., and Principal at Sidney Kimmel Cancer Center. Education includes an MBA from Stanford University (1996) and an undergraduate degree from the Massachusetts Institute of Technology (1990). |
| Kyu-Sung Lee |
Kyu-Sung Lee currently works at SAMSUNG BIOLOGICS Co., Ltd., as Executive Vice President and BeiGene Ltd., as SVP, Head-Technical Operations & Manufacturing from 2022. Dr. Lee also formerly worked at Bristol Myers Squibb Co., as Principal in 2010, Merck & Co., Inc., as Principal in 2005, Miller Brewing Co., as Biochemical Engineer, and Amoco Bioproducts, as Principal in 1995. Dr. Lee received his doctorate degree from Purdue University and undergraduate degree and graduate degree from Seoul National University of Science & Technology. |
| Marcello Damiani |
Marcello Damiani currently works at Cellarity Inc., as Director from 2019, BeOne Medicines Ltd., as Chief Technology Officer from 2025, ModernaTX, Inc., as Chief Digital & Operational Excellence Officer, and Flagship Pioneering, Inc., as Senior Partner from 2023. Mr. Damiani also formerly worked at BenevolentAI SA, as Independent Non-Executive Director from 2023 to 2024, bioMérieux SA, as Chief Information Officer & Senior Vice President from 2010 to 2015, and Moderna, Inc., as Chief Digital & Operational Excellence Officer from 2018 to 2022. Mr. Damiani received his undergraduate degree and graduate degree from Institut d'Administration Des Entreprises De Toulouse and Masters Business Admin degree in 2015 from Trium Global Emba. |
| Xiao Bin Wu |
Xiao Bin Wu currently works at China Pharmaceutical Industry Research & Dev. Association, as Vice Chairman from 2019, BeiGene (Guangzhou) Co., Ltd., as Chairman & Manager, BeiGene Pharmaceuticals (Guangzhou) Co. Ltd., as Chairman, Clover Biopharmaceuticals Ltd., as Independent Non-Executive Director from 2021, Huizhi Pharmaceutical (Dalian) Co., Ltd., as Country Manager-China from 2011, and BeOne Medicines Ltd., as President, Chief Operating Officer & GM-China from 2021. Dr. Wu also formerly worked at RDPAC, as Vice Chairman from 2008 to 2018, China National Association of Industry & Commerce, as Vice Chairman-Pharmaceutical Chamber of Commerce, Wyeth LLC, as President & Managing Director-China Region from 2004 to 2009, Bayer Healthcare Co., Ltd., as General Manager from 2001 to 2004, and Pfizer Essential Health, as President-Greater China Region from 2009 to 2018. Dr. Wu received his graduate degree in 1990 and doctorate degree in 1993 from Universität Konstanz. |
| Qing Qing Yi |
Qing Qing Yi currently works at Hanhui Pharmaceutical Co. Ltd. (China), as Vice Chairman from 2017, JD Health International, Inc., as Non-Executive Director from 2020, BeOne Medicines Ltd., as Independent Non-Executive Director from 2014, and Hillhouse Capital Group Ltd., as Partner. Mr. Yi also formerly worked at Genor Biopharma Holdings Ltd., as Chairman from 2018 to 2021, Shanghai Junshi Biosciences Co., Ltd., as Non-Executive Director from 2016 to 2021, Gossamer Bio, Inc., as Director, and HiberCell, Inc., as Director. Mr. Yi received his Masters Business Admin degree in 2003 from the University of Southern California and undergraduate degree in 1995 from Shanghai Maritime University. |
| Olivier Brandicourt |
Olivier Brandicourt currently works at AvenCell Therapeutics, Inc., as Chairman, Alnylam Pharmaceuticals, Inc., as Independent Director from 2020, National Committee on United States-China Relations, Inc., as Director, BeOne Medicines Ltd., as Independent Non-Executive Director from 2024, Dewpoint Therapeutics, Inc., as Director from 2020, Vaxcyte, Inc., as Independent Director from 2025, and International Federation of Pharmaceutical Manufacturers, as Council Member. Dr. Brandicourt also formerly worked at Sanofi-Aventis (Singapore) Pte Ltd., as Chief Executive Officer, Sanofi, as Chief Executive Officer & Director from 2015 to 2019, Pharmaceutical Research & Manufacturers of America, as Chairman in 2019, The Children's Aid Society, Inc., as Vice Chairman, Sanofi Biotechnology SAS, as Chairman, Bayer HealthCare AG, as Chairman-Management Board from 2013 to 2015, Pfizer Manufacturing Ireland Unlimited Co., as Managing Director in 2007, Pfizer Ltd., as Managing Director from 2004 to 2007, BenevolentAI SA, as Independent Non-Executive Director from 2022 to 2024, Pfizer Inc., as President & General Manager-Emerging Markets in 2013, Warner-Lambert Co., as Vice President from 1998 to 2000, Bayer AG, as Executive Council Member, European Federation of Pharmaceutical Industries & Assns, as Vice President & Member, Parke, Davis & Co. LLC, as Vice President & General Manager from 1998 to 2000, and Odyssey Acquisition SA, as Principal. Dr. Brandicourt received his graduate degree and doctorate degree from Universite Paris Est Creteil Val De Marne and undergraduate degree from Université de Paris 5 René Descartes. |
| Michael J. Goller |
Michael J. Goller currently works at DBV Technologies SA, as Director from 2015, BeOne Medicines Ltd., as Independent Non-Executive Director from 2015, Replimune Group, Inc., as Independent Director from 2025, and Baker Bros. Advisors LP, as Partner from 2005. Mr. Goller also formerly worked at diaDexus, Inc., as Director from 2005 to 2010, Levo Therapeutics, Inc., as Director from 2017 to 2019, J.P. Morgan Partners LLC, as Associate from 1993 to 2003, and Merrill Lynch & Co., Inc., as Investment Banker from 1997 to 1999. Mr. Goller received his graduate degree and Masters Business Admin degree from The Wharton School of the University of Pennsylvania and undergraduate degree in 1997 from The Pennsylvania State University. |
| Ranjeev Krishana |
Ranjeev Krishana currently works at Sironax Ltd., as Director, Immunocore Holdings Plc, as Non-Executive Director from 2024, BeOne Medicines Ltd., as Lead Independent Director, and Baker Bros. Advisors LP, as Head of International Investments. Mr. Krishana also formerly worked at Pfizer Inc., as Director in 2007, Pfizer Inc., as Senior Regional Director in 2011, Andersen Consulting (Minnesota), as Consultant in 1997, and Accenture LLC, as Manager in 2001. Mr. Krishana received his graduate degree in 2001 from Harvard University and undergraduate degree in 1995 from Brown University. |
